ACC/AHA release revised UA/NSTEMI guidelines

Heart Attack :: ACC/AHA release revised UA/NSTEMI guidelines

The American College of Cardiology and the American Heart Association have jointly released revised Guidelines for the Management of Patients with Unstable Angina (UA)/Non-ST- Elevation Myocardial Infarction (NSTEMI).

Major changes to the guidelines include:
suggesting an initial non-invasive set of preliminary tests, such as a stress test, echocardiogram or radionuclide angiogram;
recommending the use of anti-platelet therapy clopidogrel for at least one year after receiving a drug-eluting stent;
highlighting the importance of more intense lipid and blood pressure control;
and advising cessation of non-steroidal anti-inflammatory drugs (NSAIDS) use for all UA/NSTEMI patients during hospitalization.

Coronary artery disease (CAD) is the leading cause of death in the United States, and UA and NSTEMI are acute manifestations of this condition. In 2004, the National Center for Health Statistics reported 669,000 hospitalizations for UA and 896,000 for myocardial infarction. Unstable angina, which causes chest pain and discomfort, occurs when a coronary artery is partially blocked. Myocardial infarction, or heart attack, occurs when a coronary artery is completely blocked, cutting off blood flow to the heart resulting in death of heart muscle.

The ability to detect and treat these conditions earlier has greatly improved over the last several years. ?New evidence from pivotal trials over the past five years has been gathered together in these guidelines to give physicians up-to-date and detailed information on which treatment options will provide the best possible outcomes for their patients,? said Nanette K. Wenger, M.D., F.A.C.C., F.A.H.A., a member of the guidelines writing committee and professor of medicine in the Division of Cardiology at Emory University School of Medicine in Atlanta. ?This is a major educational document for health professionals, and I trust it will become part of the core teaching for medical students, residents and graduate physicians.?

The guidelines, which were last published in 2002, have been developed for cardiovascular specialists, emergency room physicians and healthcare professionals who evaluate and treat patients with acute coronary syndrome. They focus on the diagnosis, treatment and management of patients with UA and the closely related condition of NSTEMI.

The 2002 guidelines recommended an early invasive strategy ? diagnostic angiography and revascularization ? as the way to treat UA/NSTEMI patients. The revised guidelines differentiate more extensively between high- and low-risk UA/NSTEMI groups, and recommend an early invasive strategy for unstable and high risk patients, with an initial conservative (non-invasive) strategy ? stress test, echocardiogram or radionuclide study ? as a possible treatment option in stabilized UA/NSTEMI patients and low risk patients. Risk status is determined by risk scores.

For clinical practitioners, the revised guidelines emphasize secondary prevention, recommendations that should be continued after the UA/NSTEMI patient is discharged from the hospital to reduce risk of a recurrent heart attack. ?We are emphasizing the use of ACE inhibitors---drugs that protect the muscle--- and prescribing aldosterone receptor blockade, a new drug category that wasn?t available previously for people with heart failure,? said Wenger. ?High-dose antioxidant vitamin supplements such as beta carotene, vitamins E and C and folic acid for secondary prevention are no longer recommended because results from clinical trials have shown no benefit and possible harm.? There is also a greater emphasis on smoking cessation.

Also new in the guidelines is the call for more intense lipid and blood pressure control. More stringent LDL cholesterol-lowering therapy and blood pressure management is recommended for UA/NSTEMI patients. LDL (?bad? cholesterol) should be lower than 100 mg/dL and ideally reduced to 70 mg/dL. Blood pressure should be lower than 140/90 and for those with diabetes or chronic kidney disease, a reading lower than 130/80 is recommended.

Because platelets are thought to play a key role in recurrent heart attack, the anti-platelet therapy clopidogrel is now recommended for at least one year after placement of a drug-eluting stent and shorter term for bare metal stent and with medical therapy. ?In addition we are emphasizing the value of intensive, long-term platelet therapy,? said Wenger.

Additional updates to the guidelines include recommendations to discontinue the use of hormone replacement therapy in postmenopausal women; add troponin biomarkers as markers of cardiac damage and B-type natriuretic peptide (BNP) markers as potentially useful for cardiac risk assessment; and stop the usage of non-steroidal anti-inflammatory drugs (NSAIDS) for all UA/NSTEMI patients during hospitalization.




(Heart Attack :: ACC/AHA release revised UA/NSTEMI guidelines published at SpiritIndia on Tuesday, August 7, 2007)

Heart Attack

Search more information on Heart Attack, Heart Attack books

Recently posted related articles on Heart Attack :

1. Heart Attack :: Eating your greens could prove life-saving if a heart attack strikes
2. Heart Disease :: Job strain doubles the risk of a second heart attack
3. Heart Attack :: Panic attacks associated with increased risk of cardiovascular events
4. Heart Attack :: New imaging test could help prevent heart attacks
5. Heart Attack :: Rehabilitation significantly underused after heart attack and bypass surgery
6. Diabetes :: ACTOS is associated with a 38 percent lower risk of heart attack
7. Heart Attack :: New WHO pocket-charts to identify heart attack & stroke risk
8. Diabetes :: Long-term use of diabetes drug increases heart attack risk by more than 40 percent
9. Heart Attack :: Screening family members prevents 4 in 10 premature heart attacks
10. Stent :: Drug coated stents raises risks in heart attack patients

Most related articles:

- Heart Attack :: ACC/AHA release revised UA/NSTEMI guidelines
- Diabetes :: Diabetes appears to increase risk of death for patients with acute coronary syndromes - 8.6
- Heart :: GSK's Arixtra for treatment of acute coronary syndromes approved in Europe - 7.7
- Heart Attack :: Fish oil good for heart attack patients - 7.5
- Heart Disease :: Reducing Heart Attack Risk - 7.2
- Heart Attack :: Master cardiac stem cells offer cure for heart attack - 6.7
- Heart :: MUSC helps turn heart guidelines into lifelines - 6.6
- Heart Disease :: New heart attack treatment unveiled - 6.6
- Cholesterol :: Cholesterol in stroke patients exceeds national guidelines - 6.5
- Heart Attack :: Emotional recovery helpful to heart attack patients - 6.5

Heart Attack - recent related articles/news stories:

- Oxycholesterol cholesterol may pose greatest heart disease risk
- Injection NRG1 may reverse heart attack damage
- New iPS therapy pioneered for heart attacks
- Effient to reduce heart attack risk in angioplasty patients
- Nuts and peanut butter may reduce heart attack risk

»»   Vaccine :: Underinsured children receive fewer vaccines
««   ADHD :: ADHD appears to be associated with depressed dopamine activity in brain

Home | Cancer | Therapies | Diet | Herbs | Heart | Skin | Cosmetic Surgery | Arthritis | Allergies | Eyes | GIT | Glossary | List

AYUSH = Ayurveda - Yoga - Unani - Siddha - Homeopathy -- Health articles

The information provided on SpiritIndia.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Spirit India comply with the HONcode principles for trustworthy health information.
Health, Business, Science, Sports, Entertainment, Technology
©2002-2009 SpiritIndia.com